What's new?

Sofinnova Partners Announces Sale of Corvidia Therapeutics to Novo Nordisk

Novo Nordisk acquires Corvidia for $2.1B with an upfront payment of $725M in cash   Sofinnova Partners co-founded Corvidia as its sole seed financial investor in 2015 with serial entrepreneur Michael Davidson   PARIS, France – June 11, 2020 - Sofinnova Partners, a leading European life sciences venture capital firm...

Abivax Announces German Regulatory Approval of ABX464 Covid-19 Phase 2b/3 COVID-19 Clinical Trial

Second regulator to approve "miR-AGE" Phase 2b/3 trial after clearance of French authorities (ANSM)   1,034-patient placebo-controlled trial to test oral ABX464's triple effect in COVID-19 patients: antiviral, anti-inflammatory and tissue repair Bpifrance provided €36 million non-dilutive funding for ABX464 COVID-1...

Comet Bio Announces Positive Clinical Trial Results for its Prebiotic Arrabina™

Arrabina™ Arabinoxylan GI tolerance no different than placebo   SCHAUMBURG, Ill., May 20, 2020 /PRNewswire/ -- Comet Bio announced today the successful completion of its randomized, placebo-controlled, crossover clinical trial evaluating the gastrointestinal (GI) tolerability and prebiotic effects of its Arabinoxyl...

HotSpot Therapeutics Completes $65 Million Series B Financing to Advance Pipeline of Novel Allosteric Medicines

Financing Accelerates Development of First-in-Class Therapies with Genetically Validated Mechanisms for Treatment of Autoimmune Diseases, Rare Diseases and Cancer   BOSTON, May 21, 2020 /PRNewswire/ -- HotSpot Therapeutics, Inc, a biotechnology company pioneering the discovery and development of first-in-class allo...

Abivax Receives ANSM and Ethics Committee Clearance to Test its Development Candidate ABX464 in 1,034 COVID-19 Patients in Randomized Phase 2B/3 Clinical Trial

French regulator, ANSM, as well as Ethics Committee, CPP, have cleared ABX464 for Phase 2b/3 “ miR-AGE ” testing

ABX464 Inhibits Replication of SARS-CoV-2 (COVID-19) in Reconstituted Human Respiratory Epithelium Model

ABX464 is the only drug candidate with a potential triple action for COVID-19 treatment: antiviral, anti-inflammatory and tissue repair

Genespire and SR-Tiget announce strategic alliance for the development of transformative gene therapies for genetic diseases and disclose collaboration focus

Pre-clinical data from SR-Tiget, included in the alliance with Genespire, to be presented at ASGCT 23rd Annual Meeting

1 ... 4 5 6